Evofem Biosciences Files Current Report

Ticker: EVFM · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1618835

Sentiment: neutral

Topics: 8-K, disclosure, financial-reporting

Related Tickers: EVFM

TL;DR

EVFM filed an 8-K on 3/28 for a 3/27 event. Standard disclosure.

AI Summary

Evofem Biosciences, Inc. filed an 8-K on March 28, 2024, reporting an event on March 27, 2024. The filing is a current report under Regulation FD and includes financial statements and exhibits. The company, formerly known as Neothetics, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This 8-K filing indicates a routine update or disclosure from Evofem Biosciences, Inc., which could contain important information for investors regarding company events or financial status.

Risk Assessment

Risk Level: low — This filing appears to be a standard current report (8-K) with no immediate indication of significant financial distress or major corporate changes.

Key Players & Entities

FAQ

What specific event is reported in this 8-K filing dated March 28, 2024?

The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting an event that occurred on March 27, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits.

What was Evofem Biosciences, Inc. previously named?

Evofem Biosciences, Inc. was formerly known as Neothetics, Inc., with a date of name change on September 5, 2014.

In which state is Evofem Biosciences, Inc. incorporated?

Evofem Biosciences, Inc. is incorporated in Delaware.

What is the principal executive office address for Evofem Biosciences, Inc.?

The principal executive offices are located at 7770 Regents Road, Suite 113-618, San Diego, CA 92122.

What is the IRS Employer Identification Number for Evofem Biosciences, Inc.?

The IRS Employer Identification Number for Evofem Biosciences, Inc. is 20-8527075.

Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-28 17:11:11

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Evofem Biosciences, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. The Company is posting to the "Investors" portion of its website at www.evofem.com a copy of its current corporate slide presentation. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate presentation prepared as of March 27, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOFEM BIOSCIENCES, INC. Date: March 28, 2024 By: /s/ Ivy Zhang Ivy Zhang Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing